임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

20건 표시

2상모집 중· Generalized Myasthenia Gravis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
리드: 암젠
상세 →NCT06987539
2상모집 중· Thyroid Eye Disease
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
리드: 암젠
상세 →NCT07438405
2상모집 중· Extensive Stage Lung Small Cell Cancer
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
협력: 암젠
상세 →NCT07203053
2상모집 중· Extensive Stage Lung Small Cell Carcinoma
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
협력: 암젠
상세 →NCT07423585
2상모집 중· Overweight or Obesity and Elevated Liver Fat
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
리드: 암젠
상세 →NCT07441252
2상모집 중· CD19 Positive
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
협력: 암젠
상세 →NCT07222579
2상모집 중· Advanced Solid Tumors
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
리드: 암젠
상세 →NCT07172919
2상모집 중· Advanced Neuroendocrine Carcinomas of The Digestive System
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
협력: 암젠
상세 →NCT07061080
2상모집 중· Astrocytic Tumor
Study of How Safe and Effective Tarlatamab is in Brain Cancers
협력: 암젠
상세 →NCT06776250
2상모집 중· Metastatic Prostate Cancer
A Study of Tarlatamab for People With Prostate Cancer
협력: 암젠
상세 →NCT07111507
2상모집 중· Systemic Lupus Erythematosus
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
리드: 암젠
상세 →NCT06570798
2상모집 중· Metastatic/Locally Advanced Small-Cell Lung Cancer
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
협력: 암젠
상세 →NCT07016230
2상모집 중· DLL3-expressing Tumors
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
협력: 암젠
상세 →NCT06788938
2상모집 중· Acute Lymphoblastic Leukemia
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
협력: 암젠, 화이자
상세 →NCT06533748
2상모집 중· Acute Myeloid Leukemia
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
협력: 암젠
상세 →NCT06529731
2상모집 중· Neuromyelitis Optica Spectrum Disorder
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
리드: 암젠
상세 →NCT05549258
2상모집 중· Multiple Myeloma
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
협력: 암젠, GSK
상세 →NCT05789303
2상모집 중· B-cell Acute Lymphoblastic Leukemia
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
협력: 암젠
상세 →NCT04746209
2상모집 중· Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
협력: 암젠, 다케다
상세 →NCT03263572
2상모집 중· Cancer
The Drug Rediscovery Protocol (DRUP Trial)
협력: 암젠, 아스트라제네카, BMS, GSK, 일라이 릴리, 머크(MSD), 노바티스, 화이자
상세 →NCT02925234

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.